---
title: "TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295201925.md"
description: "TD Cowen analyst Phil Nadeau maintained a Buy rating on Voyager Therapeutics (VYGR). The stock closed at $3.13. Nadeau, who covers the healthcare sector with a strong track record, is part of an analyst consensus that rates VYGR as a Strong Buy, with an average price target of $17.00."
datetime: "2026-08-07T08:08:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295201925.md)
  - [en](https://longbridge.com/en/news/295201925.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295201925.md)
generator: "portal-rs"
---

# TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)

TD Cowen analyst Phil Nadeau maintained a Buy rating on Voyager Therapeutics yesterday. The company’s shares closed yesterday at $3.13.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Nadeau covers the Healthcare sector, focusing on stocks such as Biogen, Voyager Therapeutics, and Enliven Therapeutics. According to TipRanks, Nadeau has an average return of 9.8% and a 48.84% success rate on recommended stocks. 

Currently, the analyst consensus on Voyager Therapeutics is a Strong Buy with an average price target of $17.00.

### Related Stocks

- [VYGR.US](https://longbridge.com/en/quote/VYGR.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)

## Related News & Research

- [Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47%](https://longbridge.com/en/news/295659316.md)
- [Voyager Therapeutics (VYGR) to Announce Quarterly Earnings on Wednesday](https://longbridge.com/en/news/294203494.md)
- [Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/297408646.md)
- [Rapport Therapeutics to Join Cantor Global Healthcare Conference Fireside Chat](https://longbridge.com/en/news/297773944.md)
- [Alliance Global Partners Sticks to Their Buy Rating for Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/297544479.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**